Multifunctional Nanoagent for Thrombus-Targeted Fibrinolytic Therapy

Abstract

The applicability of a FXIIIa-targeted thrombolytic nanoagent in the treatment of thromboembolism was demonstrated in vitro and in vivo. Future studies are planned to investigate the safety profile and overall efficacy of this class of nanoagents.